Year: 2026
Type: article
Study design: Observational Study
Abstract: Generalized anxiety disorder (GAD) is a common, chronic condition, and real-world comparative data on imipramine and escitalopram are limited. Therefore, it is of interest to compare their effectiveness and safety in outpatients with newly diagnosed GAD over 24 weeks. In this prospective observational study at Gandhi Medical College and Hamidia Hospital, Bhopal, 100 patients received imipramine (n=50) or escitalopram (n=50) at the treating physician's discretion. Anxiety was assessed with the Hamilton Anxiety Rating Scale (HAM-A) at baseline and at weeks 4, 12 and 24, and adverse drug reactions were recorded. Mean HAM-A score fell from 35.05 to 9.42 (73.1%) with imipramine and from 36.08 to 8.95 (75.2%) with escitalopram. Drowsiness was significantly more frequent with imipramine (36% vs 2%; P<0.001). Thus, both drugs produced comparable, substantial reductions in anxiety, with better tolerability for escitalopram; randomized trials are warranted.
Source: Bioinformation
Author: Yogesh Jain
Institution: Chirayu Medical College & Hospital
Language: English
Subfield: Experimental and Cognitive Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: hybrid
OpenAlex ID: W7225140176
